• Pathogen Reduction Device Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets  
    Terumo BCT's Mirasol shows efficacy against virus causing COVID-19 in plasma and platelets. (Photos: Terumo BCT)
  • Pathogen Reduction Device Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets  
    Terumo BCT's Mirasol shows efficacy against virus causing COVID-19 in plasma and platelets. (Photos: Terumo BCT)

Blood

Pathogen Reduction Device Shows Efficacy Against Virus Causing COVID-19 in Plasma and Platelets  

Data from a new study suggests that a medical device that uses vitamin B2 and ultraviolet light for treating human blood products is effective against the virus that causes COVID-19. The study results, generated by Terumo BCT in collaboration with top researchers from Colorado State University, have been accepted for publication by Vox Sanguinis, a peer-reviewed medical journal covering haematology.

Blood is considered vital medicine, and it is the backbone of the healthcare system. While there is no evidence that blood transfusions transmit COVID-19, some blood centres are using Mirasol to treat platelets and plasma as an additional layer of safety.

In some parts of the world, healthcare providers also treat convalescent plasma with Mirasol. The International Society for Blood Transfusion (ISBT) Global Blood Safety Working Party recommends, where feasible, pathogen inactivation of plasma to control residual risks of transfusion transmitted infection diseases and to ally concern about possible super infections with SARS-CoV-2, the virus that causes COVID-19.2

Using riboflavin (vitamin B2) and ultraviolet light, Mirasol is designed to reduce the pathogen load of various disease-causing agents such as viruses, parasites and bacteria in blood products before they are transfused to patients. Mirasol also inactivates white blood cells to help reduce certain transfusion reactions.

“Mirasol is one of the tools we are using to help equip healthcare providers in their fight against COVID-19,” said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT. “We are deploying our existing innovations to benefit as many patients as possible.”

Mirasol is CE marked for platelets, plasma and whole blood and is in routine use in more than 20 countries throughout Europe, the Middle East, Africa, Asia and Latin America. The system is not approved for sale in the US and Canada.

There are no approved devices or therapies for specific treatment of COVID-19. 

More information online


Digital Edition

Lab Asia 32.2 April

April 2025

Chromatography Articles - Effects of small deviations in flow rate on GPC/SEC results Mass Spectrometry & Spectroscopy Articles - Waiting for the present to catch up to the future: A bette...

View all digital editions

Events

FORUMESURE

Apr 22 2025 Hammamet, Tunisia

Korea Lab 2025

Apr 22 2025 Kintex, South Korea

Analytica Anacon India & IndiaLabExpo

Apr 23 2025 Mumbai, India

Analitika Expo 2024

Apr 23 2025 Moscow, Russia

Expomed Eurasia

Apr 24 2025 Istanbul, Turkey

View all events

Great Job...
The latest issue will be with you shortly
Sign up to Labmate for FREE.
Register and get the eBulletin, a Monthly email packed with the latest Laboratory products, news and services. Join us and get the latest Laboratory information first.